Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed recent transactions involving the purchase of 1,300 American Depositary Receipts (ADRs) by its board members and executives. This ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Lars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Money Movers' to discuss Jorgensen's comments on demand in 2025, if demand is waning for GLP-1 drugs, and much more.

Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of drug-enhancing technology.

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

The global diabetes and obesity epidemic is driving another expansion of Novo Nordisk’s drug-manufacturing operations at its 264-acre campus in Clayton. The company will begin a $65 million expansion ...

Novo Nordisk Fonden tjener ikke kun milliarder på vægttabs- og diabetesmedicin ved at eje Novo Nordisk. Fonden ejer også en af verdens største leverandører af ingredienser til den globale ...